Novo Nordisk (NVO) and Valo Health said Wednesday that they plan to discover and develop new treatments for obesity, type 2 diabetes, and cardiovascular disease.
The collaboration is an expansion of an agreement the companies signed in 2023 to develop up to 11 drug programs mainly concerning cardiovascular disease.
Under the terms of the amended agreement, Valo will receive an upfront payment, equity investment, and a potential near-term milestone payment of $190 million in total. The company is also eligible to receive milestone payments of approximately $4.6 billion for up to 20 drug programs.
Shares of Novo Nordisk were up more than 2% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。